SLEDAI-2K

Assess disease activity in lupus

The global unit selector only affects unanswered questions
1.Seizure?
2.Psychosis?
3.Organic Brain Syndrome?
4.Visual Disturbance?
5.Cranial Nerve Disorder?
6.Lupus Headache?
7.CVA?
8.Vasculitis?
9.Arthritis?
10.Myositis?
11.Urinary casts?
12.Hematuria?
13.Pyuria?
14.Proteinuria?
15.Rash?
16.Mucosal Ulcers?
17.Pleurisy?
18.Pericarditis?
19.Low Complement?
20.Increased DNA Binding?
21.Fever?
22.Thrombocytopenia?
23.Leukopenia?
24.Alopecia?
Created by

1. Seizure?

More Information

Recent onset, exclude metabolic, infectious or drug causes

Created by
0/24 completed

About this Calculator

The SLEDAI was originally developed to determine disease activity in patients with lupus.

SLEDAI-2K was developed as a modification of SLEDAI in order to include persistent, active disease in those descriptors that had previously only considered new or recurrent occurrences. Specifically SLEDAI-2K allows persistent active disease in alopecia, mucous membrane ulcers, rash, and proteinuria to be scored.

SLEDAI-2K was validated against the original SLEDAI as a predictor for mortality and as a measure of global disease activity. It was also found to be equivalent to SLEDAI in describing changes in disease activity from one visit to the next.

References

Gladman DD, Ibañez D, Urowitz MB.

Systemic lupus erythematosus disease activity index 2000.

Journal of Rheumatology 2002, 29 (2): 288-91

Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH, and the Committee on Prognosis Studies in SLE.

The development and validation of the SLE Disease Activity Index (SLEDAI). Arthritis Rheum 1992;35:630-40.

Legal Notices and Disclaimer

© 2020 QxMD Software Inc., all rights reserved. No part of this service may be reproduced in any way without express written consent of QxMD. This information should not be used for the diagnosis or treatment of any health problem or disease. This information is not intended to replace clinical judgment or guide individual patient care in any manner. Click here for full notice and disclaimer.